PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
5.62%
Net income growth 5-10% – Moderate. Peter Lynch would look for expansions or new product lines to accelerate profit gains.
3.20%
D&A up to 5% yoy – Manageable. Seth Klarman would see normal expansions if revenue justifies the extra depreciation.
No Data
No Data available this quarter, please select a different quarter.
22.07%
SBC 20-30% yoy – High. Howard Marks would see potential margin or per-share pressures unless returns on these hires are clear.
81.65%
Working capital above 30% yoy – Very high. Philip Fisher would demand clarity on whether the buildup is strategic or signals inefficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
50.82%
AP above 30% yoy – High. Philip Fisher would suspect possible cash strain or very aggressive use of supplier credit.
28.44%
20-30% yoy – Could tie up significant cash. Howard Marks would look at specific accounts causing the growth.
-17.77%
A negative yoy shift in other non-cash items can lower reported volatility. Benjamin Graham would confirm it is not concealing real operational costs or artificially inflating net income.
18.75%
Operating cash flow growth 15-20% – Very strong. Benjamin Graham would verify if cyclical or stable demand drives this improvement.
-1425.00%
A negative yoy CapEx shift boosts near-term FCF if capacity is adequate. Benjamin Graham would see it as beneficial unless future growth is sacrificed.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1425.00%
A negative yoy shift suggests smaller outflows or net inflows if disposals exceed invests. Benjamin Graham would see a short-term FCF benefit unless growth is compromised.
No Data
No Data available this quarter, please select a different quarter.
-0.29%
A negative yoy figure could mean fewer or no new shares or even net buybacks. Benjamin Graham would see it as positive unless expansions need capital that internal cash cannot provide.
No Data
No Data available this quarter, please select a different quarter.